Abstract
Background: After the re-introduction of ImmunoCAP ((R)) ISAC sIgE 112 on the market, we undertook a study to evaluate the performance of this multipl......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
